Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | MARS2 | Q96GW9 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.57 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.57 |
| ▸ | RPS17 | P08708 | 1/20 | 0.57 |
| ▸ | RPSA | P08865 | 1/20 | 0.57 |
| ▸ | RPS2 | P15880 | 1/20 | 0.57 |
| ▸ | RPL35A | P18077 | 1/20 | 0.57 |
| ▸ | RPL7 | P18124 | 1/20 | 0.57 |
| ▸ | RPL17 | P18621 | 1/20 | 0.57 |
| ▸ | RPS4Y1 | P22090 | 1/20 | 0.57 |
| ▸ | RPS3 | P23396 | 1/20 | 0.57 |
| ▸ | RPS12 | P25398 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240806 | 1.00 | ASAH2 (0.64) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL13930323 | 1.00 | ASAH2 (0.64) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL4234491 | 1.00 | ASAH2 (0.64) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL13930313 | 1.00 | ASAH2 (0.64) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL13930315 | 1.00 | ASAH2 (0.64) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL12213638 | 1.00 | ASAH2 (0.64) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL4238306 | 1.00 | ASAH2 (0.64) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL2522862 | 0.95 | ASAH2 (0.59) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL19328599 | 0.94 | ASAH2 (0.58) | ASAH2MAPTALDH1A1LMNACYP3A4 | |
| SCHEMBL19352897 | 0.94 | ASAH2 (0.58) | ASAH2MAPTALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024211811-A2 | METHODS AND COMPOSITIONS FOR ANTIBODY-DRUG CONJUGATES | FREZENT BIOLOGICAL SOLUTIONS, INC. (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2024211811-A2 | METHODS AND COMPOSITIONS FOR ANTIBODY-DRUG CONJUGATES | FREZENT BIOLOGICAL SOLUTIONS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2022261752-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PARKER ALEX (CA) | 2022-12-22 | — | — | WO | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| WO-2020023390-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20170029454-A1 | NKT CELL LIGANDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-02 | — | — | US | disclosed |
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2015-10-22 | — | — | US | disclosed |
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2015-10-22 | — | — | US | disclosed |
| US-8937100-B2 | Cosmetic composition containing calcium citrate and N-acylated aminoalcohol derivative | COGNIS IP MANAGEMENT GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20140086863-A1 | Cosmetic Composition | COGNIS IP MANAGEMENT GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-20110256241-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2011-10-20 | — | — | US | disclosed |
| US-20110256241-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2011-10-20 | — | — | US | disclosed |
| WO-2010108619-A1 | COSMETIC COMPOSITION CONTAINING CALCIUM CITRATE AND N-ACYLATED AMINOALCOHOL DERIVATIVE TO PREVENT DRY SKIN AND SIGNS OF CUTANEOUS AGEING | COGNIS IP MANAGEMENT GMBH (DE) | 2010-09-30 | — | — | WO | disclosed |
| EP-2233128-A1 | Cosmetic composition | Cognis IP Management GmbH (DE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2010-03-18 | — | — | US | disclosed |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) | 2010-03-18 | — | — | US | disclosed |
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | UNIVERSITY OF COPENHAGEN (DK) | 2009-02-26 | — | — | US | disclosed |
| US-20080268073-A1 | CERAMIDASE INHIBITOR | TAKARA BIO INC. (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20070128212-A1 | Ceramidase inhibitor | TAKARA BIO INC. (JP) | 2007-06-07 | — | — | US | disclosed |
| EP-1707211-A1 | CERAMIDASE INHIBITOR | TAKARA BIO INC. (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054526-A1 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS | LIPE, PNLIP, FAAH2 | ASAH2 17/4885MAPT 4499/4885ALDH1A1 1720/4885 |
| US-20150297576-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | ASAH2 3/4885MAPT 4005/4885ALDH1A1 1928/4885 |
| US-20110256241-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, CHKA, ASAH2 | ASAH2 3/4885MAPT 3140/4885ALDH1A1 1787/4885 |
| US-20170029454-A1 | NKT CELL LIGANDS AND METHODS OF USE | PBK, CD69, NFATC1 | ASAH2 24/4885MAPT 4842/4885ALDH1A1 2150/4885 |
| US-20080268073-A1 | CERAMIDASE INHIBITOR | ASAH2, ASAH1, GAA | ASAH2 1/4885MAPT 1700/4885ALDH1A1 745/4885 |
| US-20070128212-A1 | Ceramidase inhibitor | ASAH2, ASAH1, GAA | ASAH2 1/4885MAPT 1700/4885ALDH1A1 745/4885 |
| US-20100068302-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ASAH1, ACER2, ASAH2 | ASAH2 3/4885MAPT 4005/4885ALDH1A1 1928/4885 |
| US-20140086863-A1 | Cosmetic Composition | ASAH2, ASAH1, GLA | ASAH2 1/4885MAPT 1983/4885ALDH1A1 495/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | ASAH2 7/4885MAPT 1644/4885ALDH1A1 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.